

## **Pathogens tested for by QIAstat-Dx Respiratory SARS-CoV-2 Panel**

### **Viruses**

SARS-CoV-2 (Covid-19)

Influenza A

Influenza A subtype H1N1/2009

Influenza A subtype H1

Influenza A subtype H3

Influenza B

Coronavirus 229E

Coronavirus HKU1

Coronavirus NL63

Coronavirus OC43

Parainfluenza 1

Parainfluenza 2

Parainfluenza 3

Parainfluenza 4

Respiratory Syncytial Virus A/B

Human Metapneumovirus A/B

Adenovirus

Bocavirus

Rhino/Enterovirus

### **Bacteria**

*Mycoplasma pneumonia*

*Legionella pneumophila*

*Bordatella pertussis*

## **Sample size justification for multivariable analysis**

Nine variables were expected to be included in the multivariable model. Riley et al. suggest three criteria for sample size considerations in multivariable predictive models, where  $n$  is chosen to: 1) limit optimism in predictor effects (represented by a shrinkage factor  $>0.9$ ; this is to avoid overfitting, which can result in a model that performs well in the sample it is derived from, but does not perform well under other samples/external validation), 2) ensure a small difference ( $\leq 0.05$ ) between apparent and adjusted Nagelkerke's  $R^2$  (a measure of proportion of variance explained in the outcome; again to avoid overfitting) and 3) provide a precise estimate of overall risk. With  $n=236$  and prevalence of 40%, overall risk could be estimated within 6.5%; fixing shrinkage to 0.9 (as recommended) and with  $R^2$  of 0.3, the sample size of 236 would meet all three criteria (based on `pmsampsize` command in Stata).  $R^2$  was anticipated to be much higher, given the nature of the diagnostic test; for  $R^2$  of 0.65, this would allow all criteria to be met under the assumption that we might estimate 15 parameters based on modelling continuous variables, using restricted cubic splines.

